PT Jiwon哦-期刊文章盟盟-麦克拉Seigo盟Shiv Saidha AU -伊莱亚斯Sotirchos盟凯萨琳Zackowski AU - Min陈盟杰里王子AU -玛丽Diener-West AU -彼得·卡拉布雷西AU -丹尼尔帝国TI -正常化的脊髓多发性硬化(P06.106) DP - 2013年2月12日TA -神经病学PG - P06.106 P06.106 VI - 80 IP - 7补充4099 - //www.ez-admanager.com/content/80/7_Supplement/P06.106.short 4100 - http://n.neurology.or首页g/content/80/7_Supplement/P06.106.full所以Neurology2013 2月12;80 AB -目的:评估脊髓体积的影响(SCV)归一化的各种因素对MRI-clinical相关性。背景:脊髓(SC)病理学是常见的多发性硬化症(MS)、和措施的SC萎缩也越来越多的被利用。SCV正常化是重要的移除inter-subject变异与疾病无关的影响,尤其是在横断面研究。没有共识关于最优方法规范化SCV,与之前的研究支持使用许多不同的归一化因子。使用各种标准化因素和临床措施,我们试图评估SCV规范化的影响MRI-clinical相关性MS.DESIGN /方法:133人复发和进步的女士接受颈椎SC-MRI 3 t和临床评估,包括扩大残疾状态量表(eds)、多发性硬化功能复合(所有),和髋关节弯曲强度的定量测试(HFS)和振动觉阈值(威仕特)。SCV同样之间测量。SCV正常化是由原始SCV除以每个标准化因数(同样之间高度,number-of-slices,颅内体积(ICV))。斯皮尔曼相关系数(ρ)是用于评估临床措施SCV和个人之间的关系。并运用多元线性回归方法进一步研究多个SCV标准化因素之间的关系和个人临床措施。结果:之间有显著相关性的临床措施和原始SCV (eds:ρ= -0.20; MSFC: ρ=0.16; HFS:ρ=0.35, VST: ρ=-0.19, all p-values<0.05). Observed clinical-MRI correlations improved with normalization by number-of-slices(EDSS:ρ=-0.43; MSFC:ρ=0.33; HFS:ρ=0.38, VST:ρ=-0.40, all p-values<0.001) and height(EDSS:ρ=-0.26; MSFC:ρ=0.28; HFS:ρ=0.22, VST:ρ=-0.29, all p-values<0.01 except HFS p-value=0.02), but diminished with normalization by ICV(EDSS:ρ=-0.02,p-value=0.81; MSFC:ρ=-0.16;p-value=0.08; HFS:ρ=0.11,p-value=0.22; VST:ρ=-0.19,p-value=0.04). All normalization factors were independently associated with MSFC in a multivariable regression model(all coefficient p-values<0.05).CONCLUSIONS: SCV normalization by number-of-slices and height strengthen clinical-MRI correlations. Normalization of SCV by either of these factors should be performed to maximize the clinical utility of this measure. Normalization of SCV by multiple factors may be of utility when assessing comprehensive clinical measures.Supported by: MS Society of Canada; National MS Society.Disclosure: Dr. Oh has received research support from Teva Neuroscience and EMD Serono. Dr. Seigo has nothing to disclose. Dr. Saidha has received personal compensation for activities with MedicalLogix and Teva Neurosciences. Dr. Sotirchos has nothing to disclose. Dr. Zackowski has nothing to disclose. Dr. Chen has nothing to disclose. Dr. Prince has received personal compensation for activities with Diagnosoft, Inc. Dr. Prince has received royalty payments from technology that Johns Hopkins owns and has licensed to Diagnosoft, Inc. Dr. Prince holds stock and/or stock options in Diagnosoft, Inc. Dr. Diener-West has nothing to disclose. Dr. Calabresi has received personal compensation for activities with Biogen Idec, Teva Neuroscience, Genzyme Corporation, Vaccinex, Vertex, and Novartis. Dr. Calabresi has received research support from the National Institutes of Health, the National Multiple Sclerosis Society, Nancy Davis Foundation, Biogen Idec, Vertex, Genentech, Inc., Abbott, and Bayer. Dr. Reich has nothing to disclose.Thursday, March 21 2013, 7:30 am-12:00 pm